43 peer-reviewed studies on the supplements, nutrition, and lifestyle changes that you can start today to actively prevent your likelihood of developing invasive breast cancer. Click the orange button to the right to get started.
Rational, informed decision-making for breast cancer patients and survivors. Everyone would agree that this is the key to managing any cancer. The challenge for the BC patient is that rational, informed decision-making is almost impossible. It is important to begin all posts about ductal carcinoma in-situ by saying that this diagnosis is not cancer. It is pre-breast cancer.
I wrote a post recently about whole breast radiation in DCIS patients. Yes, this therapy reduces the risk of DCIS recurring in the same breast but doesn’t change the how the survivor lives.
I also wrote about how early stage BC is affected by tamoxifen, WBR and lumpectomy affect overall survival.
My problem with many of the breast cancer studies and statistics is that in general, quality-of-life issues are largely minimized. I am a long-term cancer survivor who lives in complete remission from his “incurable cancer.” I live an evidence-based, non-toxic, non-conventional lifestyle that has kept my cancer in complete remission since early 1999.
To learn more about DCIS and the evidence-based therapies that can help you prevent its spread into invasive breast cancer, please watch the video below:
There are dozens of evidence-based, non-toxic therapies to reduce the risk of breast cancer. Scroll down the page, post a question or comment and I will reply to you ASAP.
“Fewer than 6% of women with ductal carcinoma in situ developed contralateral breast cancer within 10 years, according to study results presented at the American Society of Breast Surgeons Annual Meeting…
“Overall survival after treatment for Ductal Carcinoma In-Situ is excellent, yet many patients overestimate their risk for local recurrence and for contralateral BC, potentially leading to a decision in favor of bilateral mastectomy…”
Few studies have examined the risk for contralateral BC after DCIS, particularly in women treated with breast-conserving surgery. Further, little data exists on factors associates with contralateral breast cancer following DCIS…”
First breast event — either contralateral BC or ipsilateral breast tumor recurrence, defined as diagnosis of invasive cancer or DCIS — served as the primary outcome…
Researchers reported higher cumulative incidence of ipsilateral breast tumor recurrence than contralateral breast cancer at 5 years (7.8% vs. 2.8%) and 10 years (14.3% vs. 5.6%)…”
Ductal carcinoma in situ (DCIS) is a non-invasive breast cancer that comprises approximately 20% of new breast cancer diagnoses. DCIS is predominantly detected by screening mammography prior to the development of any clinical symptoms.
Prognosis following a DCIS diagnosis is excellent, due to both the availability of effective treatments and the frequently benign nature of the disease. However, a DCIS diagnosis and its treatment have psychological and physical impacts that often lead to adverse changes in health-related behaviors, including changes in:
which may represent a greater threat to the woman’s overall health than the DCIS itself. Depending on age at diagnosis, women diagnosed with DCIS are 3-13 times more likely to die from non-breast cancer related causes, such as cardiovascular disease, than from breast cancer.
Thus, the maintenance and improvement of healthy behaviors that influence a variety of outcomes after diagnosis may warrant increased attention during DCIS management. This may also represent an important opportunity to promote the adoption of healthy behaviors, given that DCIS carries the psychological impact of a cancer diagnosis but also a favorable prognosis. Particular focus is needed to address these issues in vulnerable patient subgroups with pre-existing higher rates of unhealthy behaviors and demonstrated health disparities…”